Literature DB >> 25088563

Incidence and survival in late liver metastases of colorectal cancer.

Pierre Landreau1, Antoine Drouillard, Guy Launoy, Pablo Ortega-Deballon, Valérie Jooste, Côme Lepage, Jean Faivre, Olivier Facy, Anne-Marie Bouvier.   

Abstract

BACKGROUND AND AIMS: Data concerning the risk of long-term liver metastasis following surgery of colorectal cancer in the general population are scarce. The 10-year incidence and prognosis of metachronous liver metastases remain unknown.
METHODS: Among 4584 patients resected for cure for colorectal cancer recorded in two French digestive population-based cancer registries between 1985 and 2000, 602 presented metastases including liver metastases.
RESULTS: The cumulated incidence of liver metastasis was 15% at 5 years and 17% at 10 years, and was mainly related to stage at diagnosis. The 10-year cumulative incidence was 6% for stage I and 30% for stage III. The hazard ratio was 3.2 [2.4-4.3] for stage II and 6.9 [5.1-9.2] for stage III compared with stage I. Among survivors with no recurrence five years after diagnosis, 2.2% developed liver metastasis between 5 and 10 years. Resection for cure of liver metastases was performed in 35% of patients aged under 75 years and in 10% of patients over 75 (P < 0.001). After resection for cure, 10-year relative survival improved from 21% during the period 1985-1997 to 34% during the period 1998-2011 (P = 0.023). Survival in patients with liver metastasis diagnosed between six and 12 months after surgery was less than half that in patients with metastasis diagnosed later (HR: 0.6 [0.4-1.0]).
CONCLUSION: Liver metastases from colorectal cancer remain a substantial problem and continue to occur long after five years. This study furnishes unbiased figures that can be used as a reference. Liver metastases that appear late have a better prognosis.
© 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  cancer registry; colorectal cancer; incidence; long-term liver metastasis; survival

Mesh:

Year:  2015        PMID: 25088563     DOI: 10.1111/jgh.12685

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  30 in total

1.  Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.

Authors:  Marco Ravanelli; Giorgio Maria Agazzi; Elena Tononcelli; Elisa Roca; Paolo Cabassa; Gianluca Baiocchi; Alfredo Berruti; Roberto Maroldi; Davide Farina
Journal:  Radiol Med       Date:  2019-06-06       Impact factor: 3.469

2.  Growth pattern of colorectal liver metastasis as a marker of recurrence risk.

Authors:  R L Eefsen; P B Vermeulen; I J Christensen; O D Laerum; M B Mogensen; H C Rolff; G G Van den Eynden; G Høyer-Hansen; K Osterlind; B Vainer; M Illemann
Journal:  Clin Exp Metastasis       Date:  2015-03-31       Impact factor: 5.150

3.  The Impact of a Hepatobiliary Multidisciplinary Team Assessment in Patients with Colorectal Cancer Liver Metastases: A Population-Based Study.

Authors:  Jennie Engstrand; Nikolaos Kartalis; Cecilia Strömberg; Mats Broberg; Anna Stillström; Tobias Lekberg; Eduard Jonas; Jacob Freedman; Henrik Nilsson
Journal:  Oncologist       Date:  2017-05-26

4.  Aberrant expression of WNK lysine deficient protein kinase 1 is associated with poor prognosis of colon adenocarcinoma.

Authors:  Huiyuan Jiang; Xin Cheng; Yanjie Liang; Yan Wang; Yiqun Li; Yaoping Li
Journal:  Ir J Med Sci       Date:  2022-02-09       Impact factor: 1.568

5.  Identification of ABCA5 among ATP-Binding Cassette Transporter Family as a New Biomarker for Colorectal Cancer.

Authors:  Peilong Bu; Yafei Xiao; Shaowen Hu; Xiaowei Jiang; Cong Tan; Mengyuan Qiu; Wanting Huang; Mengmeng Li; Quanying Li; Changjiang Qin
Journal:  J Oncol       Date:  2022-06-22       Impact factor: 4.501

6.  Development and external validation of prognostic nomograms for liver disease-free and overall survival in locally advanced rectal cancer with neoadjuvant therapy: a post cohort study based on the FOWARC trial.

Authors:  Jiaming Zhou; Tuoyang Li; Yuanlv Xiao; Jinxin Lin; Xiaoqiong Chen; Shaoyong Peng; Mingzhe Huang; Xuebin Shi; Linbin Cai; Pinzhu Huang; Meijin Huang
Journal:  Ann Transl Med       Date:  2022-06

7.  High expression of homeobox B2 predicts poor survival of colon adenocarcinoma by enhancing tumor proliferation and invasion.

Authors:  Shengjie Li; Yujie Wang; Zhiqiang Xuan; Yue Zhang; Zhongxing Miao
Journal:  Ir J Med Sci       Date:  2022-03-23       Impact factor: 1.568

8.  Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients.

Authors:  Gaojie Liu; Jie Zhu; Menglei Yu; Canfeng Cai; Yu Zhou; Min Yu; Zhiqiang Fu; Yuanfeng Gong; Bin Yang; Yingru Li; Quanbo Zhou; Qin Lin; Huilin Ye; Liangtao Ye; Xiaohui Zhao; Zhihua Li; Rufu Chen; Fanghai Han; Chaoming Tang; Bing Zeng
Journal:  J Transl Med       Date:  2015-05-07       Impact factor: 5.531

9.  Preoperative CT versus diffusion weighted magnetic resonance imaging of the liver in patients with rectal cancer; a prospective randomized trial.

Authors:  Michael P Achiam; Vibeke B Løgager; Bjørn Skjoldbye; Jakob M Møller; Torben Lorenzen; Vera L Rasmussen; Henrik S Thomsen; Talie H Mollerup; Cecilie Okholm; Jacob Rosenberg
Journal:  PeerJ       Date:  2016-01-14       Impact factor: 2.984

10.  Preserved liver regeneration capacity after partial hepatectomy in rats with non-alcoholic steatohepatitis.

Authors:  David Haldrup; Sara Heebøll; Karen Louise Thomsen; Kasper Jarlhelt Andersen; Michelle Meier; Frank Viborg Mortensen; Jens Randel Nyengaard; Stephen Hamilton-Dutoit; Henning Grønbæk
Journal:  World J Hepatol       Date:  2018-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.